



14 November 2018

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT

This notice is given by Actinogen Medical Limited pursuant to section 708A(5)(e) of the Corporations Act (**ACT**).

On 14 November 2018, the Company issued 20,550,000 fully paid ordinary shares at an issue price of \$0.02 per share (the **Securities**), following the exercise of 20,550,000 unlisted 30 November 2018 options.

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Company issued the Securities without disclosure to investors under part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
3. as at the date of this notice there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a faint circular stamp.

Peter Webse
Company Secretary